Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | BRAF | P15056 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.53 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2245813 | 0.96 | LMNA (0.82) | LMNARXFP1NPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14441194 | 0.94 | LMNA (0.70) | LMNARXFP1NPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL17896338 | 0.87 | LMNA (0.62) | LMNARXFP1NPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21349098 | 0.86 | LMNA (0.61) | LMNARXFP1NPSR1ALDH1A1BRAF | |
| SCHEMBL19539979 | 0.84 | LMNA (0.58) | LMNARXFP1NPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL15528268 | 0.82 | RXFP1 (1.00) | LMNARXFP1ALDH1A1 | |
| SCHEMBL12975171 | 0.81 | GAA (0.72) | LMNANPSR1ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL12764072 | 0.80 | NPSR1 (0.94) | LMNANPSR1ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL9532585 | 0.79 | ALDH1A1 (0.91) | LMNANPSR1ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL3442947 | 0.79 | LMNA (0.69) | LMNARXFP1NPSR1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-16 | — | — | US | disclosed |
| US-20180050997-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2018-02-22 | — | — | US | disclosed |
| WO-2017189613-A1 | METHODS OF USING FASN INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2017-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050997-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | LMNA 285/4885RXFP1 4584/4885NPSR1 2115/4885 |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | LMNA 1231/4885RXFP1 4241/4885NPSR1 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.